NCT06704932View on ClinicalTrials.gov

A First-in-human Study to Investigate Safety and Tolerability of SAR446959 in Participants With Osteoarthritis of the Knee

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

December 19, 2025

Study Completion Date

December 19, 2025

Conditions
Osteoarthritis
Interventions
DRUG

SAR446959

Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection

DRUG

Placebo

Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection

Trial Locations (1)

14050

Investigational Site Number : 2760001, Berlin

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT06704932 - A First-in-human Study to Investigate Safety and Tolerability of SAR446959 in Participants With Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter